Indeed, using syngeneic mouse models of B cell lymphoma, Kuhn et al. showed that CD40L-modified CD19-targeting CAR T cells licensed APCs and enhanced endogenous anti-tumour T cell responses in vivo [101]. This evidence concerns the gene CD19 and neoplasm.